Eisai Co. Ltd.
www.eisai.com
Latest From Eisai Co. Ltd.
UK's AstronauTx Gets Cash For Alzheimer's Programs
The Dementia Discovery Fund is backing the UCL spin-off's efforts to develop therapies that modulate astrocyte function.
E2082 Discontinuation May Hit Eisai's Epilepsy Succession
Fatality of healthy volunteer in early clinical trial prompts halt of all clinical work for candidate anti-epileptic, potentially hitting Eisai's product succession strategy in a core therapeutic area.
Want To Fly In China‘s New Normal? Learn From Merck
Many multinationals are banking on novel drug products to capture China’s new growth spurt as it transforms to care centered on innovative therapies, although this could be a hard sell given the largely private pay nature of the market for such products. Q2 China growth at Merck & Co. however flew through the roof with the aid of a suite of newly launched products. So what made it a shining star?
Keeping Track: US FDA Clears Two More Biosimilars, First Non-Injectable Glucagon
The latest drug development news and highlights from our US FDA Performance Tracker.
Company Information
- Industry
-
Pharmaceuticals
- OTC, Consumer
- Therapeutic Areas
- Cancer
- Cardiovascular
- Gastrointestinal
- Gynecological, Urological
- Immune Disorders
- Infectious & Viral Diseases
- Inflammation
- Metabolic Disorders
- Musculoskeletal & Connective Tissue Disorders
- Neurology, Nervous System
- Respiratory, Pulmonary
- Alias(es)
- Ownership
- Public
- Headquarters
-
Worldwide
-
Asia
-
Pacific Rim
-
Japan
-
Japan
-
Pacific Rim
-
Asia
- Company Type
- Top Japanese Pharma
- Parent & Subsidiaries
- Eisai Co. Ltd.
- Senior Management
-
Haruo Naito, Pres. & CEO
Ryohei Yanagi, CFO
Edward Stewart Geary, CMO - Contact Info
-
Eisai Co. Ltd.
Phone: (81) 3 3817 3700
4-6-10 Koishikawa
Bunkyo-ku
Tokyo, 112-8088
Japan
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice